

2 September 2024

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Scancell Announces its Attendance at Upcoming Conferences**

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to confirm that it will be presenting at, and will also attend, several upcoming conferences and events in September, October and November 2024. Presentations at these high-profile conferences follow the significant recent progress that Scancell has made in both pre-clinical and clinical development.

These include:

- [ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit](#) taking place in Boston, Massachusetts, USA from 9-10 September.  
Mandeep Sehmi, Head of Business Development, will be attending the conference.
- [ESMO Congress 2024](#) taking place in Barcelona, Spain from 13-17 September  
Dr Nermeen Varawalla, Chief Medical Officer, and Dr Robert Miller, Medical Director, will be attending the conference.
- [Vaccines & Immunotherapies Online Symposium](#) taking place virtually on Thursday, 26 September.  
Samantha Paston, Head of Translational Research, will be presenting.  
Title: Phase 2 clinical trial, a DNA cancer vaccine, SCIB1, in patients with advanced unresectable melanoma receiving nivolumab + ipilimumab  
Time: 4.20pm BST
- [Festival of Biologics](#) taking place in Basel, Switzerland from 15-17 October.  
Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer, will be presenting.  
Session Title: Therapeutic Vaccine Development  
Title: Clinical update on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination  
Date and Time: Wednesday, 16 October at 5.30pm CEST
- [16<sup>th</sup> Annual PEGS Europe](#) taking place in Barcelona, Spain and virtually from 5-7 November.  
Mireille Vankemmelbeke, Principal Scientist, will be presenting.  
Session Title: Antibody-Based Cancer Therapies: Novel Targets  
Title: Fucosyl-GM1: A Versatile Target for SCLC Therapy  
Date and Time: Tuesday, 5 November at 5.05pm CEST

If you would like to arrange a meeting with management, please contact [commercial.enquiries@scancell.co.uk](mailto:commercial.enquiries@scancell.co.uk).

**-ENDS-**

**For further information, please contact:**

**Scancell Holdings plc** +44 (0) 20 3709 5700  
Dr Jean-Michel Cosséry, Non-Executive Chairman  
Professor Lindy Durrant, CEO

**Panmure Liberum Limited** (Nominated Advisor and Joint Broker) +44 (0) 20 7886 2500  
Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)  
Rupert Dearman (Corporate Broking)

### **About Scancell**

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCQKDBDKBKBOCK